RecruitingPhase 2Phase 3NCT02657785

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy

Sponsor

Navy General Hospital, Beijing

Enrollment

100 participants

Start Date

Sep 1, 2010

Study Type

INTERVENTIONAL

Conditions

Primary Central Nervous System Lymphoma

Summary

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of chemotherapy drugs (called R-IDARAM) along with medication injected directly into the fluid around the spinal cord (intrathecal chemotherapy) to treat primary central nervous system lymphoma (PCNSL) — a type of cancer that develops in the brain or spinal cord. **You may be eligible if...** - You have been diagnosed with primary central nervous system lymphoma (a lymphoma originating in the brain or spinal cord) - You are newly diagnosed or have relapsed (cancer came back after prior treatment) - You are in adequate overall health to receive intensive chemotherapy - Your liver and kidney function are adequate **You may NOT be eligible if...** - You have lymphoma that originated outside the central nervous system and spread to it - You have serious liver, kidney, or heart problems - You have an active serious infection - You are pregnant or breastfeeding - You have a condition that would prevent you from safely receiving any of the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGR-IDARAM plus intrathecal chemotherapy

R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.